Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia

Haematologica

Volumn 100, Issue 7, 2015, Pages 927-934

  Konopleva, Marina ^a   Thall, Peter F ^a   Yi, Cecilia Arana ^a   Borthakur, Gautam ^a   Coveler, Andrew ^b   Bueso Ramos, Carlos ^a   Benito, Juliana ^a   Konoplev, Sergej ^a   Gu, Yongchuan ^c   Ravandi, Farhad ^a   Jabbour, Elias ^a   Faderl, Stefan ^a   Thomas, Deborah ^a   Cortes, Jorge ^a   Kadia, Tapan ^a   Kornblau, Steven ^a   Daver, Naval ^a   Pemmaraju, Naveen ^a   Nguyen, Hoang Q ^a   Feliu, Jennie ^a   Lu, Hongbo ^a   Wei, Caimiao ^a   Wilson, William R ^c   Melink, Teresa J ^d   Gutheil, John C ^d   Andreeff, Michael ^a   Estey, Elihu H ^b   Kantarjian, Hagop ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d Proacta Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PIMONIDAZOLE; PR104; UNCLASSIFIED DRUG; ALKYLATING AGENT; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; CHLORMETHINE DERIVATIVE; HIF1A PROTEIN, HUMAN; NITROIMIDAZOLE DERIVATIVE; PR-104; PRODRUG; TUMOR ANTIGEN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ADVERSE DRUG REACTION; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; COLITIS; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; ENTEROCOLITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOXIA; IMMUNOHISTOCHEMISTRY; LIVER FAILURE; MALE; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; SMALL INTESTINE OBSTRUCTION; THROMBOCYTOPENIA; TOXICITY; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; BONE MARROW; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; REMISSION;

ADULT; AGED; ANEMIA; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOMARKERS; BONE MARROW; CARBONIC ANHYDRASE IX; CARBONIC ANHYDRASES; ENTEROCOLITIS; FEMALE; GENE EXPRESSION; HUMANS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEUTROPENIA; NITROGEN MUSTARD COMPOUNDS; NITROIMIDAZOLES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRODRUGS; RECURRENCE; REMISSION INDUCTION; THROMBOCYTOPENIA;

EID: 84936081114     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.118455     Document Type: Article

References (35)

1. Estey EH. Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol. 2013;88(4):318-327.
2. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29(5):591-599.
3. Benito J, Shi Y, Szymanska B, et al. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One. 2011;6(8):e23108.
4. Azab AK, Hu J, Quang P, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood. 2012;119(24):5782-5794.
5. Rapin N, Bagger FO, Jendholm J, et al. Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood. 2014;123(6):894-904.
6. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-732.
7. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441(7092):437-443.
8. Wellmann S, Guschmann M, Griethe W, et al. Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia. 2004;18(5):926-933.
9. Matsunaga T, Imataki O, Torii E, et al. Elevated HIF-1alpha expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy. Leuk Res. 2012; 36(6):e122-124.
10. Ng KP, Manjeri A, Lee KL, et al. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood. 2014;123(21):3316-3326.
11. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393-410.
12. Patterson AV, Ferry DM, Edmunds SJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res. 2007;13(13):3922-3932.
13. Jamieson SM, Gu Y, Manesh DM, et al. A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells. Biochem Pharmacol. 2014;88(1):36-45.
14. Jameson MB, Rischin D, Pegram M, et al. A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldoketo reductase 1C3, in patients with solid tumors. Cancer Chemother Pharmacol. 2010;65(4):791-801.
15. McKeage MJ, Gu Y, Wilson WR, et al. A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients. BMC Cancer. 2011;11:432.
16. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
17. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
18. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649.
19. Thall PF, Nguyen HQ, Estey EH. Patient-specific dose finding based on bivariate outcomes and covariates. Biometrics. 2008;64(4):1126-1136.
20. Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Zhao S, Lin Y, Xu W, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324(5924):261-265.
22. Patel K, Choy SS, Hicks KO, et al. A combined pharmacokinetic model for the hypoxia- targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity. Cancer Chemother Pharmacol. 2011;67(5):1145-1155.
23. Foehrenbacher A, Patel K, Abbattista MR, et al. The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104. Front Oncol. 2013;3:263.
24. Davila ML. Neutropenic enterocolitis: current issues in diagnosis and management. Current infectious disease reports. 2007;9(2):116-120.
25. Ebert EC, Hagspiel KD. Gastrointestinal manifestations of leukemia. Journal of gastroenterology and hepatology. 2012;27(3):458-463.
26. Gorschluter M, Mey U, Strehl J, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 2005;75(1):1-13.
27. Hogan WJ, Letendre L, Litzow MR, et al. Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin Proc. 2002;77(8):760-762.
28. Gu Y, Tingle MD, Wilson WR. Glucuronidation of anticancer prodrug PR- 104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy. J Pharmacol Exp Ther. 2011;337(3):692-702.
29. Eliasson P, Jonsson JI. The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol. 2010;222(1):17-22.
30. Winkler IG, Barbier V, Wadley R, et al. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood. 2010;116(3):375-385.
31. Konopleva M, Handisides D, Lorente GA, et al. Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias. J Clin Oncol. 2012;30(Abstract 6585).
32. Deeb G, Vaughan MM, McInnis I, et al. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res. 2011;35(5):579-584.
33. Koivunen P, Lee S, Duncan CG, et al. Transformation by the (R)-enantiomer of 2- hydroxyglutarate linked to EGLN activation. Nature. 2012;483(7390):484-488.
34. Lee K, Qian DZ, Rey S, et al. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci USA. 2009;106(7):2353-2358.
35. Rapisarda A, Uranchimeg B, Sordet O, et al. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 2004; 64(4):1475-1482.